ACCORD News

ACCORD News

Bursaries for patient and public involvement in research

ACCORD: Bursaries for patient and public involvement in research

MHRA suspends use of certain Gadolinium contrast agents (GdCAs), and restricts uses of others

MHRA suspends use of certain Gadolinium contrast agents (GdCAs), and restricts uses of others.

MHRA Recall of Gadolinium-containing contrast agents

A class 2 medicine recall – action within 48 hours – has now been issued by the MHRA for Magnevist (Bayer plc) and Omniscan Solution (GE Healthcare).

Changes to IRAS from 18 October 2017

Changes to IRAS from 18 October 2017

Changes to IRAS from 28 June 2017

Changes to IRAS - Effective June 28th 2017

MHRA Statement on Lab Inspections

Statement from the MHRA on inspections of Labs analysing human samples as part of a clinical trial.

New Accord Brochure

The 2016 Accord brochure can be found HERE

Management of Deviations & Violations Training Material

Management of Deviations & Violations Training Materials available.

New HRA Approval Documents

New HRA Approval documents are available